Cameron Lambert, MD
Cardiovascular Disease · Greensboro, NCNPI 1346583747
Payments from drug & device makers
Across 449 payments — averaging $1356.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$255K
- Masimo Corporation$244K
- Novartis$34K
- Boston Scientific$21K
- Biosense Webster, Inc.$20K
- Sanofi-aventis U.S. LLC$13K
- plus $23K from 28 others
What the payments were for
- Consulting fees$24,63525%
- Speaking & faculty fees$12,15312%
- Grants$41,50042%
- Travel & lodging$9,76210%
- Food & beverage$10,86711%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 61 | $255,085 |
| Masimo Corporation | 88 | $244,093 |
| Novartis | 9 | $34,012 |
| Boston Scientific | 66 | $20,581 |
| Biosense Webster, Inc. | 49 | $20,063 |
| Sanofi-aventis U.S. LLC | 16 | $12,605 |
| Eli Lilly | 35 | $10,193 |
| Abbott | 27 | $8,312 |
| Biotronik Inc. | 16 | $1,218 |
| Philips North America LLC | 7 | $1,168 |
| Irhythm Technologies, Inc. | 10 | $263 |
| Atricure, Inc. | 3 | $249 |
| Amgen | 8 | $169 |
| Impulse Dynamics (USA) Inc. | 3 | $147 |
| Pfizer | 8 | $122 |
| Cvrx, Inc. | 2 | $121 |
| Johnson & Johnson | 7 | $113 |
| E.r. Squibb & Sons, L.L.C. | 7 | $112 |
| Boehringer Ingelheim | 5 | $89 |
| Merck | 3 | $60 |
| Edwards Lifesciences | 2 | $48 |
| Lexicon Pharmaceuticals, Inc. | 2 | $38 |
| Elutia, Inc. | 2 | $36 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $31 |
| Abiomed | 1 | $28 |
| Bayer | 1 | $26 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $24 |
| Cardiva Medical, Inc. | 1 | $21 |
| Kestra Medical Technology Services, Inc. | 1 | $17 |
| Cook Medical LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Teleflex LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$15,464
- GENERAL BRADY$5,000
- GENERAL - THERAPIES$2,022
- IGT Devices Und$918
- WATCHMAN Access System$481
- AVEIR$449
- Quadra Assura CRT Defibrillator$308
- Acticor 7 VR-T DX$243
- LINQ II$233
- OPTIMIZER$229
- SET and rainbow SET$209
- SedLine$209
- Patient SafetyNet System$209
- EnSite Velocity System Mapping D$175
- Micra$161
- TightRail$150
- Reveal LINQ$134
- Rhythmia Mapping System$131
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$130
- General - CRM_CRM$124
How this compares
$609,116 in reported general payments places this provider in the 90th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 656 | $598,347 |
| XareltoRivaroxaban | 180 | $167,538 |
| EntrestoSacubitril/Valsartan | 46 | $65,897 |
| FarxigaDapagliflozin Propanediol | 19 | $18,455 |
| JardianceEmpagliflozin | 15 | $12,371 |
| Dofetilide | 75 | $7,052 |
| Metoprolol Succinate | 373 | $6,385 |
| Amiodarone Hcl | 193 | $4,025 |
| Mexiletine Hcl | 21 | $4,023 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 103 | $3,447 |
| Flecainide Acetate | 71 | $3,208 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $2,771 |
| Potassium Chloride | 60 | $1,344 |
| Nebivolol Hcl | 20 | $794 |
| Propafenone Hcl | 19 | $762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $122 | $598,347656 claims |
| Johnson & JohnsonXarelto | $113 | $167,538180 claims |
| NovartisEntresto | $34,012 | $65,89746 claims |
| AstraZenecaFarxiga | $14 | $18,45519 claims |
| Boehringer IngelheimJardiance | $89 | $12,37115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Greensboro
- Jagadeesh GanjiGreensboro$1.7M
- Kenneth HiltyGreensboro$1.6M
- Michael CooperGreensboro$613K
- Bridgette ChristopherGreensboro$261K
- John AlexanderDurham$76.8M
- Christopher GrangerDurham$24.7M
- Jonathan PicciniDurham$14.3M
- Adrian HernandezDurham$13.2M
- Gary FelkerDurham$12.7M
- Robert MentzDurham$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.